WO2006084139A3 - An implantable interferon-containing device - Google Patents
An implantable interferon-containing device Download PDFInfo
- Publication number
- WO2006084139A3 WO2006084139A3 PCT/US2006/003857 US2006003857W WO2006084139A3 WO 2006084139 A3 WO2006084139 A3 WO 2006084139A3 US 2006003857 W US2006003857 W US 2006003857W WO 2006084139 A3 WO2006084139 A3 WO 2006084139A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- implantable
- containing device
- day
- period
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 µg/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06720233A EP1877077A2 (en) | 2005-02-03 | 2006-02-03 | An implantable interferon-containing device |
CA002596966A CA2596966A1 (en) | 2005-02-03 | 2006-02-03 | Implantable osmotic device for continuous delivery of suspension formulations |
JP2007554243A JP2008528698A (en) | 2005-02-03 | 2006-02-03 | Implantable interferon-containing devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65022605P | 2005-02-03 | 2005-02-03 | |
US60/650,226 | 2005-02-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006084139A2 WO2006084139A2 (en) | 2006-08-10 |
WO2006084139A3 true WO2006084139A3 (en) | 2006-10-19 |
WO2006084139A8 WO2006084139A8 (en) | 2007-12-27 |
Family
ID=36587040
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/003857 WO2006084139A2 (en) | 2005-02-03 | 2006-02-03 | An implantable interferon-containing device |
PCT/US2006/003861 WO2006084141A2 (en) | 2005-02-03 | 2006-02-03 | Suspension formulation of interferon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/003861 WO2006084141A2 (en) | 2005-02-03 | 2006-02-03 | Suspension formulation of interferon |
Country Status (5)
Country | Link |
---|---|
US (2) | US7655254B2 (en) |
EP (2) | EP2361630A1 (en) |
JP (1) | JP2008528698A (en) |
CA (1) | CA2596966A1 (en) |
WO (2) | WO2006084139A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
CA2507522C (en) | 2002-12-13 | 2015-02-24 | Durect Corporation | Oral drug delivery system |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
LT2767292T (en) | 2004-09-17 | 2016-12-12 | Durect Corporation | Sustained Local Anesthetic Composition Containing SAIB |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
EP2361630A1 (en) * | 2005-02-03 | 2011-08-31 | Intarcia Therapeutics, Inc | Implantable drug delivery device comprising particles and an osmotic pump |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
CN101453982B (en) | 2006-05-30 | 2011-05-04 | 精达制药公司 | Two-piece, internal-channel osmotic delivery system flow modulator |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
US8337883B2 (en) | 2006-11-03 | 2012-12-25 | Durect Corporation | Transdermal delivery systems |
US20130150943A1 (en) | 2007-01-19 | 2013-06-13 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
US20080177373A1 (en) | 2007-01-19 | 2008-07-24 | Elixir Medical Corporation | Endoprosthesis structures having supporting features |
US8814930B2 (en) * | 2007-01-19 | 2014-08-26 | Elixir Medical Corporation | Biodegradable endoprosthesis and methods for their fabrication |
RU2440097C2 (en) * | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it |
CA2706658A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
NZ592113A (en) * | 2008-10-15 | 2012-04-27 | Intarcia Therapeutics Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
WO2010146536A1 (en) * | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
WO2011007327A2 (en) * | 2009-07-16 | 2011-01-20 | Koninklijke Philips Electronics N.V. | Suspension for therapeutic use and device for delivering said suspension |
EP3323423B1 (en) * | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2012159945A1 (en) * | 2011-05-20 | 2012-11-29 | Ares Trading S.A. | Ifn-beta compositions, preparation methods and uses thereof |
EA201490837A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
DE112012003457T5 (en) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV) |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
TW201334791A (en) * | 2011-11-23 | 2013-09-01 | Durect Corp | Radiation-sterilized biodegradable drug delivery compositions |
CN105120659A (en) | 2013-03-15 | 2015-12-02 | 度瑞公司 | Compositions with a rheological modifier to reduce dissolution variability |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
EP3134068B1 (en) | 2014-04-21 | 2021-07-21 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
EP3509601A1 (en) | 2014-04-21 | 2019-07-17 | Heron Therapeutics, Inc. | A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam |
US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9855156B2 (en) | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9259339B1 (en) | 2014-08-15 | 2016-02-16 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
EA201892448A1 (en) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
CN113143536B (en) | 2016-05-16 | 2022-08-30 | 万能医药公司 | Opening support |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219572A (en) * | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
WO1999029306A1 (en) * | 1997-12-12 | 1999-06-17 | Biohybrid Technologies, Inc. | Devices for cloaking transplanted cells |
WO2000029206A1 (en) * | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
US6468961B1 (en) * | 1996-12-20 | 2002-10-22 | Alza Corporation | Gel composition and methods |
WO2004056338A2 (en) * | 2002-12-19 | 2004-07-08 | Alza Corporation | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
RU2189221C2 (en) | 1996-02-02 | 2002-09-20 | Элзэ Копэрейшн | Method and device for administering active substance and method for treating prostate carcinoma patients |
US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
ZA981610B (en) * | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
MY125870A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
DK1041975T3 (en) * | 1997-12-22 | 2002-11-04 | Alza Corp | Speed-controlling membranes for controlled drug delivery devices |
DE69822208T2 (en) | 1997-12-29 | 2005-04-28 | Alza Corp., Mountain View | OSMOTIC ADMINISTRATION SYSTEM WITH PUSHROOM RESTRAINT MECHANISM |
JP4494629B2 (en) | 1997-12-30 | 2010-06-30 | インターシア セラピューティクス,インコーポレイティド | Beneficial agent supply system with membrane plug |
CA2356860C (en) | 1998-12-31 | 2006-11-07 | Alza Corporation | Osmotic delivery system having space efficient piston |
US6703225B1 (en) * | 1999-01-12 | 2004-03-09 | Sumitomo Pharmaceuticals Company, Limited | Interferon-α |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
CA2361424C (en) * | 1999-02-08 | 2009-04-28 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US20030059376A1 (en) * | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
DE60023361T2 (en) | 1999-12-21 | 2006-04-27 | Alza Corp., Mountain View | VALVE FOR OSMOTIC DEVICES |
EP1274459B1 (en) * | 2000-04-19 | 2005-11-16 | Genentech, Inc. | Sustained release formulations comprising growth hormone |
AU2587002A (en) * | 2000-11-03 | 2002-05-15 | Biomedicines Inc | Method for short-term and long-term drug dosimetry |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
JP2004535464A (en) | 2001-07-20 | 2004-11-25 | インターミューン インコーポレイテッド | How to treat liver fibrosis |
NZ533435A (en) * | 2001-11-14 | 2007-10-26 | Alza Corp | Injectable depot compositions and uses thereof |
CA2467239A1 (en) | 2001-11-14 | 2003-05-22 | Alza Corporation | Catheter injectable depot compositions and uses thereof |
MXPA04004664A (en) * | 2001-11-14 | 2004-09-10 | Alza Corp | Injectable depot composition. |
CA2484052C (en) * | 2002-04-11 | 2011-06-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
CN1668279A (en) | 2002-06-17 | 2005-09-14 | 阿尔萨公司 | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
ATE376854T1 (en) | 2002-06-26 | 2007-11-15 | Alza Corp | MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS |
US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
KR20060002922A (en) | 2003-03-31 | 2006-01-09 | 알자 코포레이션 | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
JP2006521897A (en) | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | Osmotic pump with means for dissipating internal pressure |
US20050175701A1 (en) * | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
EP2361630A1 (en) | 2005-02-03 | 2011-08-31 | Intarcia Therapeutics, Inc | Implantable drug delivery device comprising particles and an osmotic pump |
US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
CN101453982B (en) | 2006-05-30 | 2011-05-04 | 精达制药公司 | Two-piece, internal-channel osmotic delivery system flow modulator |
-
2006
- 2006-02-03 EP EP11165436A patent/EP2361630A1/en not_active Withdrawn
- 2006-02-03 CA CA002596966A patent/CA2596966A1/en not_active Abandoned
- 2006-02-03 JP JP2007554243A patent/JP2008528698A/en active Pending
- 2006-02-03 WO PCT/US2006/003857 patent/WO2006084139A2/en active Application Filing
- 2006-02-03 WO PCT/US2006/003861 patent/WO2006084141A2/en active Application Filing
- 2006-02-03 EP EP06720233A patent/EP1877077A2/en not_active Withdrawn
- 2006-02-03 US US11/347,601 patent/US7655254B2/en active Active
- 2006-02-03 US US11/347,109 patent/US20060263433A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219572A (en) * | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
US6468961B1 (en) * | 1996-12-20 | 2002-10-22 | Alza Corporation | Gel composition and methods |
WO1999029306A1 (en) * | 1997-12-12 | 1999-06-17 | Biohybrid Technologies, Inc. | Devices for cloaking transplanted cells |
WO2000029206A1 (en) * | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
US20040157951A1 (en) * | 1998-11-13 | 2004-08-12 | Wolf David E. | Monodisperse preparations useful with implanted devices |
WO2004056338A2 (en) * | 2002-12-19 | 2004-07-08 | Alza Corporation | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
Also Published As
Publication number | Publication date |
---|---|
US7655254B2 (en) | 2010-02-02 |
EP1877077A2 (en) | 2008-01-16 |
CA2596966A1 (en) | 2006-08-10 |
WO2006084139A8 (en) | 2007-12-27 |
EP2361630A1 (en) | 2011-08-31 |
US20060263433A1 (en) | 2006-11-23 |
JP2008528698A (en) | 2008-07-31 |
WO2006084141A3 (en) | 2006-09-21 |
US20060251618A1 (en) | 2006-11-09 |
WO2006084141A8 (en) | 2006-11-09 |
WO2006084141A2 (en) | 2006-08-10 |
WO2006084139A2 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006084139A8 (en) | An implantable interferon-containing device | |
HK1123213A1 (en) | Reduction of dizziness, a side effect associated with pirfenidone therapy | |
AU2003220312A1 (en) | Patient controlled activation with implantable drug delivery devices | |
AU2003295614A8 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
GB2389791B (en) | Implantable drug delivery pump | |
AU2003220317A8 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
AU2003243305A8 (en) | Implantable medication delivery device | |
AU2003217531A1 (en) | Ocular drug delivery systems and use thereof | |
AU2003287734A1 (en) | Implantable device for delivering cardiac drug therapy | |
AU2003284018A1 (en) | Medical device for neural stimulation and controlled drug delivery | |
EP1482914A4 (en) | Implantable drug delivery system | |
MXPA05005315A (en) | Medical devices incorporating deuterated rapamycin for controlled delivery thereof. | |
MXPA05006994A (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia. | |
HUP0402661A3 (en) | Formulation and dosage form for the controlled delivery of therapeutic agents | |
DE60327843D1 (en) | MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE | |
WO2006113978A3 (en) | Insulins combinations | |
WO2009067431A3 (en) | Controlled drug delivery using a zein layer modified with levulinic acid | |
DE602008006700D1 (en) | ||
WO2008091704A3 (en) | Treatment of cushing's syndrome and autism | |
AU2003231260A8 (en) | Catechin multimers as therapeutic drug delivery agents | |
WO2004103267A3 (en) | Methods to administer epothilone d | |
WO2005123113A3 (en) | Interferon compositions and methods of use thereof | |
WO2007081858A3 (en) | Zein coated medical device | |
TW200509985A (en) | Drug delivery system for sub-Tenon administration of fine particles | |
GB0228305D0 (en) | Therapeutic composition for respiratory delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2596966 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007554243 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006720233 Country of ref document: EP |